Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147302 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01147302 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 18 participants.
The verdict
NCT01147302, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the safety, effect, and pharmacology of C1 Esterase Inhibitor (human) in kidney transplant patients with acute Antibody-Mediated Rejection (AMR).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL C1 Esterase Inhibitor (Human)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-08-24 |
| Est. Completion | 2013-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147302
The ClinicalTrials.gov registry entry for NCT01147302 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01147302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147302 about?
NCT01147302 is a clinical study titled "A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection". The purpose of this research study is to evaluate the safety, effect, and pharmacology of C1 Esterase Inhibitor (human) in kidney transplant patients with acute Antibody-Mediated Rejection (AMR).
What is the current status of trial NCT01147302?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2011-08-24. Estimated completion is 2013-06-28.
What interventions are being tested in trial NCT01147302?
The interventions under investigation include: Placebo (BIOLOGICAL), C1 Esterase Inhibitor (Human) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01147302?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.